deltatrials
Completed PHASE2 NCT00001066

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections
Interventions Didanosine Lamivudine Zidovudine
Updated 6 times since 2017 Last updated: Mar 1, 2011 Primary completion: Jan 31, 2001

A PHASE2 clinical study on HIV Infections, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Glaxo Wellcome
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Atlanta, United States, Augusta, United States, Baltimore, United States, Bayamón, Puerto Rico, Birmingham, United States, Boston, United States, Brooklyn, United States, Buffalo, United States, Charleston, United States and 57 more location s